1
Mark C Benyunes: Therapy of autoimmune disease in a patient with an inadequate response to a TNF-α inhibitor. Genentech, Wendy M Lee, May 4, 2010: US07708994 (36 worldwide citation)

The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNFα-inhibitor.


2
Mark C Benyunes: Therapy of autoimmune disease in a patient with an inadequate response to a TNF-α inhibitor. Genentech, Wendy M Lee, July 12, 2011: US07976838 (2 worldwide citation)

The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNFα-inhibitor.


3
Mark C Benyunes: Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor. Genentech, Genentech, September 4, 2008: US20080213280-A1

The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNFα-inhibitor.


4
Mark C Benyunes: Therapy of autoimmune disease in a patient with an inadequate response to TNF-alpha inhibitor. Genentech, Genentech, October 14, 2004: US20040202658-A1

The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNF-inhibitor.


5
Mark C Benyunes: Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor. Genentech, Genentech, October 26, 2006: US20060240008-A1

The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNFα-inhibitor.


6
Mark C Benyunes: Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor. Genentech, December 8, 2011: US20110300136-A1

The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNFα-inhibitor.